vs
Side-by-side financial comparison of WARRIOR MET COAL, INC. (HCC) and Bio-Techne (TECH). Click either name above to swap in a different company.
WARRIOR MET COAL, INC. is the larger business by last-quarter revenue ($458.6M vs $295.9M, roughly 1.5× Bio-Techne). WARRIOR MET COAL, INC. runs the higher net margin — 15.8% vs 12.8%, a 2.9% gap on every dollar of revenue. On growth, WARRIOR MET COAL, INC. posted the faster year-over-year revenue change (52.1% vs -6.4%). Over the past eight quarters, WARRIOR MET COAL, INC.'s revenue compounded faster (7.5% CAGR vs 4.2%).
Warrior Met Coal, Inc. (ticker HCC) is a U.S.-headquartered mining enterprise that produces and distributes high-grade metallurgical coal, a key raw material for steel production. It serves steel manufacturers and industrial clients across core markets including North America, Europe, and Asia.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
HCC vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $458.6M | $295.9M |
| Net Profit | $72.3M | $38.0M |
| Gross Margin | 36.7% | 64.6% |
| Operating Margin | 17.3% | 18.4% |
| Net Margin | 15.8% | 12.8% |
| Revenue YoY | 52.1% | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | $1.37 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $458.6M | — | ||
| Q4 25 | $384.0M | $295.9M | ||
| Q3 25 | $328.6M | — | ||
| Q2 25 | $297.5M | $317.0M | ||
| Q1 25 | $299.9M | $316.2M | ||
| Q4 24 | $297.5M | $297.0M | ||
| Q3 24 | $327.7M | $289.5M | ||
| Q2 24 | $396.5M | $306.1M |
| Q1 26 | $72.3M | — | ||
| Q4 25 | $23.0M | $38.0M | ||
| Q3 25 | $36.6M | — | ||
| Q2 25 | $5.6M | $-17.7M | ||
| Q1 25 | $-8.2M | $22.6M | ||
| Q4 24 | $1.1M | $34.9M | ||
| Q3 24 | $41.8M | $33.6M | ||
| Q2 24 | $70.7M | $40.6M |
| Q1 26 | 36.7% | — | ||
| Q4 25 | 29.5% | 64.6% | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 23.9% | 62.7% | ||
| Q1 25 | 18.1% | 67.9% | ||
| Q4 24 | 23.1% | 65.3% | ||
| Q3 24 | 29.3% | 63.2% | ||
| Q2 24 | 34.1% | 66.4% |
| Q1 26 | 17.3% | — | ||
| Q4 25 | 9.0% | 18.4% | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 2.6% | -7.5% | ||
| Q1 25 | -5.8% | 12.2% | ||
| Q4 24 | -1.4% | 16.0% | ||
| Q3 24 | 11.9% | 13.8% | ||
| Q2 24 | 17.9% | 15.0% |
| Q1 26 | 15.8% | — | ||
| Q4 25 | 6.0% | 12.8% | ||
| Q3 25 | 11.1% | — | ||
| Q2 25 | 1.9% | -5.6% | ||
| Q1 25 | -2.7% | 7.1% | ||
| Q4 24 | 0.4% | 11.7% | ||
| Q3 24 | 12.7% | 11.6% | ||
| Q2 24 | 17.8% | 13.3% |
| Q1 26 | $1.37 | — | ||
| Q4 25 | $0.43 | $0.24 | ||
| Q3 25 | $0.70 | — | ||
| Q2 25 | $0.11 | $-0.11 | ||
| Q1 25 | $-0.16 | $0.14 | ||
| Q4 24 | $0.02 | $0.22 | ||
| Q3 24 | $0.80 | $0.21 | ||
| Q2 24 | $1.35 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $233.2M | $172.9M |
| Total DebtLower is stronger | $154.4M | $260.0M |
| Stockholders' EquityBook value | — | $2.0B |
| Total Assets | $2.8B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $233.2M | — | ||
| Q4 25 | $300.0M | $172.9M | ||
| Q3 25 | $336.3M | — | ||
| Q2 25 | $383.3M | $162.2M | ||
| Q1 25 | $454.9M | $140.7M | ||
| Q4 24 | $491.5M | $177.5M | ||
| Q3 24 | $583.2M | $187.5M | ||
| Q2 24 | $709.0M | $152.9M |
| Q1 26 | $154.4M | — | ||
| Q4 25 | $154.3M | $260.0M | ||
| Q3 25 | $154.1M | — | ||
| Q2 25 | $153.9M | $346.0M | ||
| Q1 25 | $153.8M | $330.0M | ||
| Q4 24 | $153.6M | $300.0M | ||
| Q3 24 | $153.5M | $300.0M | ||
| Q2 24 | $153.3M | $319.0M |
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | $2.0B | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | $1.9B | ||
| Q1 25 | $2.1B | $2.0B | ||
| Q4 24 | $2.1B | $2.1B | ||
| Q3 24 | $2.1B | $2.1B | ||
| Q2 24 | $2.0B | $2.1B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $2.5B | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $2.6B | $2.6B | ||
| Q4 24 | $2.6B | $2.7B | ||
| Q3 24 | $2.6B | $2.7B | ||
| Q2 24 | $2.6B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.07× | 0.13× | ||
| Q3 25 | 0.07× | — | ||
| Q2 25 | 0.07× | 0.18× | ||
| Q1 25 | 0.07× | 0.16× | ||
| Q4 24 | 0.07× | 0.14× | ||
| Q3 24 | 0.07× | 0.14× | ||
| Q2 24 | 0.07× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
